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CD27 distinguishes two phases in bone marrow infiltration of splenic marginal zone
lymphoma
Aims: To investigate CD27 expression in splenic mar-
ginal zone lymphoma (SMZL), an indolent low-grade
B-cell lymphoma with constant involvement of the
bone marrow, especially with an intrasinusoidal pat-
tern. It is not clear if the neoplastic clone is composed of
virgin or somatically mutated B cells. CD27 is reported
to be a hallmark of memory B cells.
Methods and results: We evaluated 64 bone marrow
biopsy specimens (BMBs) from 36 patients with SMZL
for the expression of CD27. For comparison, splenec-
tomy specimens of patients with traumatic splenic
rupture or with SMZL were used. All BMBs showed
lymphomatous infiltration. When located in the mar-
row sinusoids, neoplastic cells were CD27– in all cases
and therefore corresponded to naive B cells. In
nodular ⁄ interstitial infiltration, the cells were CD27+
and therefore corresponded to memory B cells. No
difference in immunohistochemical expression of B and
T antibodies was found between intrasinusoidal and
interstitial ⁄ nodular infiltration. CD27 was constantly
expressed in the splenic marginal zone of normal
spleen, surgically removed for trauma, and in seven out
of 10 spleens with SMZL.
Conclusion: We propose the existence of two different
phases of neoplastic progression with, first, expansion
of a virgin B clone in the bone marrow and, following
exposure to antigen, a re-colonization of the bone
marrow.
Keywords: bone marrow, CD27, intrasinusoidal infiltration, naive and memory B cells, splenic marginal zone
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Introduction
CD27 is an antigen involved in T–B-cell interaction and
is expressed on both T and B cells.1 The function of CD27
is not completely known but it seems to be involved
in promoting lymphocyte expansion and effector cell
formation through interaction with its ligand CD70.2
CD27 has been recently identified as a specific marker for
memory B cells.3,4 Memory B cells carry somatically
mutated variable region genes and constantly express
CD27, while naive B cells do not.5 The unmutated naive
CD27– population comprises 60% of peripheral blood
B cells.6 Three-quarters of these cells are CD5– and
constitute the naive precursor of germinal centre cells.
The memory CD27+ B-cell population is represented by
somatically mutated postgerminal centre cells and
comprises 40% of peripheral blood B cells in humans,
in contrast to 5% in mice.6 The majority of B cells in the
rat splenic marginal zones are naive B cells, as judged by
the lack of somatic hypermutation, that may be ligand
selected.7
Memory B cells are present in the human adult
splenic marginal zone. The vast majority of marginal
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zone B cells in the adult spleen express CD27.1 In
contrast, the splenic marginal zone of infants and
young children is populated by naive B cells, which
are replaced by memory B cells in a time frame of
2–5 years.8
Splenic marginal zone lymphoma (SMZL) was ori-
ginally purported to originate from postgerminal centre
memory B cells that usually have mutated immuno-
globulin heavy-chain variable (VH) genes.
9 However,
the vast majority of SMZL expresses both IgD and IgM,
which is more typical of naive cells with unmutated
VH genes.
About half of the cases studied by Algara et al. were
unmutated.10 The same percentage was found by
Bahler et al., who suggested the existence of two
different types of SMZL: one that originates from naive
B cells, in addition to one that originates from memory
marginal zone B cells. They also proposed that antigen
selection might be occurring during lymphoma-
genesis.11 Sekikawa et al. found no somatic mutation
in the IgVH sequence in cells from peripheral blood and
spleen in a case of SMZL with macroglobulinaemia.12
In order to elucidate the cell of origin and the
histogenetic mechanism in SMZL, we investigated
CD27 expression in bone marrow biopsy specimens
(BMBs) in a series of 36 patients, along with a complete
immunohistochemical study using a wide panel of
antibodies.
Materials and methods
Sixty-four BMBs were obtained from 36 patients. All
patients selected for this study were diagnosed with
SMZL. The diagnosis was made on splenectomy spec-
imens or BMB. The histological study was performed on
Schaffer-fixed paraffin-embedded BMBs using haema-
toxylin–eosin, periodic acid–Schiff, Giemsa and Gomori
stains. Immunohistochemistry was performed on BMBs
by means of the avidin–biotin–peroxidase complex,
using the monoclonal antibody CD27 (Novocastra
Laboratories, Newcastle upon Tyne, UK) at a dilution
of 1 : 40, along with the following antibodies: CD45
(leucocyte common antigen), CD20, CD79a, CD43,
CD3, CD5, CD10, CD23, Bcl-2, Bcl-6. As controls, five
normal spleens following splenectomy for trauma and
10 spleens with SMZL were used.
Results
The patients included 22 men and 14 women. The
median age was 65 years (range 23–82). Twenty
patients had two or more BMBs. All BMBs had
lymphomatous infiltration ranging from 10 to 90% of
overall cellularity. An intrasinusoidal pattern of infil-
tration was evident in all cases, alone or in association
with nodular and ⁄ or interstitial patterns. In patients
with multiple BMBs, a change or increase in the nodular
component was noted, but never the opposite, i.e. a
change from nodular to intrasinusoidal. CD27 was
found to be positive in all cases which displayed nodular
infiltration (Figure 1a), while the cells in an intrasinu-
soidal location were constantly negative (Figure 1b). In
mixed infiltrations, the cells maintained this pattern of
reactivity, i.e. positivity in the nodules and negativity in
the sinuses. With the other antibodies there was no
difference between the intrasinusoidal and intersti-
tial ⁄ nodular pattern and in all cases the infiltration
was positive for CD45, CD20, CD79a, Bcl-2, and
negative for CD43, CD3, CD5, CD10, CD23, and Bcl-6.
In the splenic marginal zone of the spleen removed for
trauma, the vast majority of the cell population was
CD27+ (Figure 1c). Occasional positive cells were seen
in mantle zones and germinal centres. In the spleens
with SMZL, CD27 was found to be positive in seven out
of 10 cases (Figure 1d). However, even in negative
cases the marginal zone of residual follicles was positive.
Discussion
Naive B cells arise in the bone marrow, where they
undergo so-called ‘antigen-independent’ development.
A further phase takes place with the activation by non-
self antigens and migration from bone marrow to
spleen.13 It has been estimated that only about 15–20
million immature B cells made each day in the mouse
bone marrow emerge as mature cells in the periph-
ery.14 Naive B cells leave the bone marrow and enter
the peripheral blood as IgM+ IgD+ cells. In the
germinal centre, the antigen-dependent stage of B-cell
development takes place. The sequence and structure of
the antigen-binding site can be altered through a
process of somatic hypermutation that is targeted at
the V domain, leading to a change in the binding
affinity and specificity of the antibody.15–17 Several
studies have interpreted findings of non-random IgVH
gene utilization and V region mutation to suggest that
a lymphoma derives from a normal cell that is antigen
experienced and has passed through the germinal
centre.18,19 In addition, a second type of recombination
event, termed class switch recombination, occurs in the
germinal centres where the B cell changes its antibody
effector function, while maintaining the antigen speci-
ficity of the original antibody.20
Human CD27 is a B-cell costimulatory molecule,
which is able to inhibit the p53-independent mito-
chondrial pathway for apoptosis of B cells and is a
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marker of memory B cells.8 Molecular analysis for
mutated Ig gene rearrangements have confirmed that
CD27 expression distinguishes naive and memory
B cells.21 Within the CD27+ B-cell pool, further
heterogeneity of subsets has been described, based on
the expression of immunoglobulin surface markers.22
Patients with primary immunodeficiency disorders, in
whom a primary defect interferes with germinal centre
reaction and generation of memory B cells, show a
predominance of CD27+ B cells, perhaps reflecting a
compensatory process with respect to B-cell differenti-
ation or function.23 Expansion of mutated CD27+
B cells originating from the marginal zone compart-
ment has been reported in persistent polyclonal
B lymphocytosis.24,25 Naive B-cell expansion in the
peripheral blood is seen in one-third of hepatitis C
virus-positive patients and is not associated with
Ag-mediated activation and differentiation.26
Mature lymphoid neoplasia in bone marrow
encompasses several distinct clinicopathological enti-
ties. Although they are currently classified according
to their presumed normal counterpart, their origin
in relation to lymphocyte ontogeny is largely
unknown.
Chronic lymphocytic leukaemia (CLL), which is the
most prevalent adult leukaemia in Western countries,
has been widely investigated in order to understand
its histogenesis and provides a model for comparison
with other chronic B-cell leukaemia ⁄ lymphomas.
Previously considered to have a low propensity to
undergo IgV(D)J gene hypermutation,27–31 CLL is now
known to show an IgVH gene somatic point-mutation
in more than half of the cases.32–37 Approximately
90% of cases express CD27, implying that virtually all
B-CLL cases derive from antigen-experienced and
memory B lymphocytes.38 However, the latter study
Figure 1. a, CD27 expression in nodular infiltration of a bone marrow biopsy specimen in a case of splenic marginal zone lymphoma
(SMZL). b, Intrasinusoidal infiltration of bone marrow (arrows) shows CD27 negativity. c, Marginal zone of traumatic spleen is demarcated
by CD27+ cells. d, Neoplastic CD27+ nodule in spleen with SMZL (ABC method).
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was performed on peripheral blood cells. It is not
known if marrow lymphocytes in B-CLL express CD27
as well.
SMZL is a relatively rare type of low-grade non
Hodgkin’s B-cell lymphoma with morphological and
immunophenotypic features resembling splenic margi-
nal zone cells.39 Splenic marginal zone cells have been
considered to serve as antigen-binding and transport-
ing cells and are capable of transforming into plasma
cells.40 Activation, proliferation and the immunoglob-
ulin secretory response of splenic marginal zone B cells
are distinctive. They are the first line in the immune
reaction against blood-borne antigens,41 such as bac-
terial capsular polysaccharide typical of a thymus
independent type 2 response. In patients with Wiskott–
Aldrich syndrome or during infancy, TI-2 responses
are impaired and marginal zone cells are in fact
reduced.42,43 In a small percentage of cases, SMZL is
characterized by the presence in the peripheral blood of
lymphocytes with villous projections, which has been
termed splenic lymphoma with villous lymphocytes.44
Although this name implies a precise origin from the
splenic marginal zone, its histogenesis is a matter of
debate, since there is no specific marker for splenic
marginal zone cells.45 An origin from memory B cells
was initially supposed.46 The constant involvement of
bone marrow either intrasinusoidally or as a mixed
intrasinusoidal ⁄ nodular form is universally acknow-
ledged,47–51 and this fact could raise questions about its
splenic origin. In the present study, constant CD27
negativity has been observed in the neoplastic cells of
the bone marrow intrasinusoidal infiltration. Con-
versely, when neoplastic cells are in a nodular bone
marrow infiltration or in the splenic marginal zone,
they express CD27. Previous studies indicate that a
nodular pattern of bone marrow infiltration follows the
intrasinusoidal one.52 It is therefore conceivable that
neoplastic B cells in the nodules could have experienced
antigen while the intrasinusoidal ones have not.
Clonal heterogeneity affecting residues in the hyper-
variable region within a tumour is taken to imply
continuing antigenic drive during the process of
transformation.
In SMZL, evidence of ongoing mutation of IgVH gene
was originally observed by Dunn-Walters et al.53
Diversity in mutational status and initiation of somatic
mutation have been demonstrated in vivo by Zhu et al.
in a limited number of patients.54 Recently, in a series
of six cases randomly selected from 23 cases of SMZL,
Tierens et al. confirmed that ongoing somatic hyper-
mutation is a prominent feature of SMZL.55 In the same
study they found no statistically significant correlation
between immunoglobulin mutation status and clinical,
immunophenotypic, or genetic characteristics. Human
bone marrow is an important destination in the route
of recirculating memory cells.56 It is not known
whether this can happen without involvement of
germinal centres. In mice, Körner et al. demonstrated
that recirculating and marginal zone B-cell populations
can be generated and maintained independently of
follicles.57
According to the results of the present study, one can
hypothesize that in SMZL a naive B-cell population in
the bone marrow proliferates and after antigenic
stimulation accumulates in the splenic marginal zone,
in the bone marrow and other sites. It is clear that
further studies are needed to verify this hypothesis.
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